Publication
Advances in Personalized Cancer Management
Book Chapter - Jan 1, 2011
Früh Martin, Baty Florent, Putora Paul Martin, Brutsche Martin
Units
Doi
Link
Contact
Citation
Type
Book Title
Publication Date
Volume
Isbn Number
Pages
Publisher
Brief description/objective
The early identification of predictive molecular markers is crucial. Activating EGF receptor mutations and ALK gene rearrangements occur in a subset of patients with non-small-cell lung cancer and predict for benefit of the treatment with EGF receptor tyrosine kinase inhibitors and ALK inhibitors. The treatment of patients with resistance to these agents is currently a field of intensive research. Numerous other oncogenic driver mutations have been discovered and corresponding agents are currently being tested in preclinical and clinical studies. Genomics in lung cancer and the field of miRNA in particular hold great promise.